L Capital Partners

L Capital Partners is a venture capital and private equity firm specializing in investments in development, early, mid and later stage, growth and expansion stages. The firm typically invests in the healthcare, technology, and energy and environmental sectors. In the healthcare sector, it seeks to invest in the areas of biopharmaceuticals and medical devices and focuses on companies in which the areas of drugs and devices intersect and have passed the proof of concept and pre clinical trial milestones, with products that are already in human clinical trials or are within six months of entering into them. In technology sector, the firm spans across commercial and public sector markets and typically invests in security or defense, particularly homeland security and information technology companies, with in information technology, it focuses on Internet applications, fault-tolerant software, and the building blocks of ad hoc, tunable, self-healing networks, both in software and in semiconductors and within security or defense sector the firm focuses on network interoperability, semiconductors, sensors and sensor networks, biometrics and biodetection, networked video intelligence, tracking technology, collection and detection of nuclear and biological and chemical hazards, and industrial control systems. In the energy and environment sector, it seeks to invest in companies that could improve the quality of life with a focus on the renewable energy, clean power generation and storage, energy efficiency, emissions control, clean water and air, and greener materials and processes. In this sector, the firm typically invests between $1 million and $6 million per round. It prefers to invest in companies based in easternmost coastal states in the United States. The firm primarily invests between $1 million and $5 million in its portfolio companies. L Capital Partners was founded in 2004 and is based in New York, New York with an additional office in Tel Aviv, Israel.

Jonathan Leitersdorf

Principal

YT

Yair Talmor

Partner

OW

Oded Weiss

Partner and CFO

LY

Lin Yan

Associate

24 past transactions

Tengion

Series C in 2008
Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells. The Company has completed two Phase 2 human clinical trial in the United States with its Tengion Neo-Bladder Augment for children with neurogenic bladder due to spina bifida and in adults with neurogenic bladder due to spinal cord injury. A successful academic human clinical experience with a urinary Neo-Bladder Augment was reported in The Lancet in April 2006 by investigators from the Children's Hospital Boston. Tengion has an effective investigational new drug application (IND) for its Neo-Urinary Conduit and expects to begin a Phase 1 clinical trial in the first half of 2010 in bladder cancer patients requiring bladder removal.

Eleme Medical

Series C in 2008
Elemé Medical, Inc. is a venture backed aesthetics company dedicated to providing market-leading technology in all areas of body shaping. The newly launched SmoothShapes® XV will revolutionize how cellulite is treated and introduce exciting new protocols for pre and post liposuction care. With 50% more laser power, SmoothSpeed™ audible & visual treatment guidance and a portable, sleek console design, SmoothShapes XV is an ideal way to add non-invasive body shaping to a practice. SmoothShapes XV is the newest product launched by the Company and joins the original SmoothShapes launched in 2008, both products are a CE Marked, FDA-cleared medical devices for the temporary reduction in the appearance of cellulite. Both SmoothShapes systems are based on the company's proprietary Photomology® platform – a process that treats cellulite and subcutaneous fat by combining dynamic light and laser energy along with mechanical manipulation (vacuum and massage). The system addresses the physical manifestations of cellulite and its underlying causes providing long lasting results that patients can see and feel. Targets include plastic surgeons, aesthetic dermatologists, medical spas and other aesthetic physicians. According to Global Body Shaping Market Analysis, body shaping is one of the top growth areas in the Aesthetics market with 19% growth through the year 2012. The global aesthetics market is projected to grow from $5.0 billion in 2008 to $8.1 billion by 2011.

CeNeRx BioPharma

Series B in 2008
CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.

IntraPace, Inc.

Venture Round in 2012
IntraPace® has developed a novel implantable system to treat obesity. It is built on the proven technology used in millions of cardiac pacemakers and defibrillators each year. The abiliti® system is designed to be implanted via standard laparoscopic instruments without making any changes to the anatomy of the digestive system or placing any limitations on what a person can eat or drink.

Tengion

Series A in 2005
Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells. The Company has completed two Phase 2 human clinical trial in the United States with its Tengion Neo-Bladder Augment for children with neurogenic bladder due to spina bifida and in adults with neurogenic bladder due to spinal cord injury. A successful academic human clinical experience with a urinary Neo-Bladder Augment was reported in The Lancet in April 2006 by investigators from the Children's Hospital Boston. Tengion has an effective investigational new drug application (IND) for its Neo-Urinary Conduit and expects to begin a Phase 1 clinical trial in the first half of 2010 in bladder cancer patients requiring bladder removal.

Locus Pharmaceuticals

Series E in 2007
Locus Pharmaceuticals, Inc. engages in developing novel and small molecule therapeutic drugs to address major unmet medical needs. The company has a computational drug design technology, which is used to develop a pipeline of drug development candidates, including direct and allosteric kinase inhibitors for cancer and inflammation diseases. Locus Pharmaceuticals, Inc. was formerly known as Locus Discovery, Inc. and changed its name to Locus Pharmaceuticals, Inc. in January 2003. The company was incorporated in 1998 and is based in Blue Bell, Pennsylvania. Locus Pharmaceuticals, Inc. is a former subsidiary of Sarnoff Corporation.

iScience Interventional

Series F in 2009
iScience Interventionalâ„¢ discovers and develops microcatheter and imaging technologies that enable ophthalmologists to deliver site-specific ocular therapies. This new category of therapy is called Interventional Ophthalmology. It encompasses microcatheter-based therapies designed to access a wide range of anatomical structures within the eye to aspirate ocular fluids or deliver sterile ophthalmic solutions to the eye.

Cigierre

Acquisition in 2012
Cigierre develops, operates, and manages multiethnic restaurants.

CeNeRx BioPharma

Series A in 2005
CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.

WiSpry

Series B in 2006
WiSpry, Inc. develops fabless radio frequency semiconductor. It offers tunable RF components, digital capacitor arrays, RF evaluation kits, filters and duplexors, and power amplifiers. The company’s products are used in airbag sensors, game controllers, accelerometers, microoptics, video projection systems, and printer heads. It serves mobile handset manufacturers and network operators. The company was founded in 2002 and is based in Irvine, California. As of May 7, 2015, WiSpry, Inc. operates as a subsidiary of AAC Technologies Holdings Inc.

Evogen

Series B in 2008
Evogen, Inc. provides air sampling solutions. Its air samplers, detectors, and detection validation technology is used for military, homeland security, commercial, government, and civilian environments in United States. It offers OMNI 3000, an aerosol sampler for indoor/outdoor applications; integrated detection system, a solution for biological threat detection; and SpinCon, an aerosol collection technology for biological and certain chemical systems. The company also offers specially manufactured consumables and accessories. Its solutions are used for various applications, such as postal security, homeland security, facility security, incident response, operations security, disaster recovery, disease detection, and warfighter protection. The company was founded as Sceptor Industries, Inc. in 2001 and changed its name to Evogen, Inc. in August 2008. The company is based in Kansas City, Missouri.

WiSpry

Series C in 2009
WiSpry, Inc. develops fabless radio frequency semiconductor. It offers tunable RF components, digital capacitor arrays, RF evaluation kits, filters and duplexors, and power amplifiers. The company’s products are used in airbag sensors, game controllers, accelerometers, microoptics, video projection systems, and printer heads. It serves mobile handset manufacturers and network operators. The company was founded in 2002 and is based in Irvine, California. As of May 7, 2015, WiSpry, Inc. operates as a subsidiary of AAC Technologies Holdings Inc.

Tengion

Series C in 2007
Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells. The Company has completed two Phase 2 human clinical trial in the United States with its Tengion Neo-Bladder Augment for children with neurogenic bladder due to spina bifida and in adults with neurogenic bladder due to spinal cord injury. A successful academic human clinical experience with a urinary Neo-Bladder Augment was reported in The Lancet in April 2006 by investigators from the Children's Hospital Boston. Tengion has an effective investigational new drug application (IND) for its Neo-Urinary Conduit and expects to begin a Phase 1 clinical trial in the first half of 2010 in bladder cancer patients requiring bladder removal.

CeNeRx BioPharma

Series C in 2010
CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.

Hi-G-Tek, Inc.

Venture Round in 2006
Hi-G-Tek is the developer of a new active-RFID platform for real-time monitoring and control of critical physical assets. Their company is commercializing patented technology that enables low power, cost-effective wireless solutions for monitoring, assessing and protecting high-value physical assets and sensitive materials. Their unique solutions provide unprecedented levels of real-time security and “sensing” of key assets, whether stationary or in transit, indoors or outdoors.

WiSpry

Series B in 2008
WiSpry, Inc. develops fabless radio frequency semiconductor. It offers tunable RF components, digital capacitor arrays, RF evaluation kits, filters and duplexors, and power amplifiers. The company’s products are used in airbag sensors, game controllers, accelerometers, microoptics, video projection systems, and printer heads. It serves mobile handset manufacturers and network operators. The company was founded in 2002 and is based in Irvine, California. As of May 7, 2015, WiSpry, Inc. operates as a subsidiary of AAC Technologies Holdings Inc.

Vicini

Venture Round in 2014
Vicini develops and manufactures footwear for men and women. The company sells its products through its Milan and New York showrooms to a selected clientele, and to its boutiques. It also offers its products through stores in Europe, Russia, Asia, and Australia.

IntelliPath

Series A in 2007
IntelliPath Solutions provides Information Management consulting services to companies who leverage data as an asset of their organization. IntelliPath’s industry experience in both IT and business, in combination with our ability to align innovation and best practices, allows for successful partnerships with our clients.

Exenta, Inc.

Series A in 2008
Your business is growing quickly, but things on the manufacturing side are disconnected and unknown. Exenta, Inc. Shopfloor 3PMTM brings real-time visibility and control to the forefront. Timing : Mon - Fri 09:00 AM to 06:00 PM, Sat - Sun - Closed Address : 8 W 38th St, New York, NY 10018

CeNeRx BioPharma

Series D in 2012
CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.

El Ganso.com

Venture Round in 2015
The El Ganso style is composed of a cosmopolitan look tinged with Spanish colours and ranges from preppy American looks to the more alternative Berlin style, via a touch of English elegance. Its signature, classic and cheeky, has become the main emblem of the brand, an inspiration that can be observed in the optimism of its garments, footwear and accessories. The originality and strength of its designs can be easily recognized in the taste for details and fabrics. Every collection is designed and manufactured 100% within Europe from local raw materials in accordance with the company’s main priorities of design, quality and innovation.

Tengion

Series B in 2006
Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells. The Company has completed two Phase 2 human clinical trial in the United States with its Tengion Neo-Bladder Augment for children with neurogenic bladder due to spina bifida and in adults with neurogenic bladder due to spinal cord injury. A successful academic human clinical experience with a urinary Neo-Bladder Augment was reported in The Lancet in April 2006 by investigators from the Children's Hospital Boston. Tengion has an effective investigational new drug application (IND) for its Neo-Urinary Conduit and expects to begin a Phase 1 clinical trial in the first half of 2010 in bladder cancer patients requiring bladder removal.

Protez Pharmaceuticals

Series B in 2005
Protez Pharmaceuticals is a medical research company that discovers, develops, and commercializes antibiotics for difficult-to-treat hospital-based infections. The company focuses on differentiated intravenous and oral small molecule antibiotics to address bacterial resistant, and chronic or recurrent infections. Protez Pharmaceuticals was founded by Christopher M. Cashman in 2003 and is headquartered in Malvern, Pennsylvania.

Hi-G-Tek, Inc.

Venture Round in 2007
Hi-G-Tek is the developer of a new active-RFID platform for real-time monitoring and control of critical physical assets. Their company is commercializing patented technology that enables low power, cost-effective wireless solutions for monitoring, assessing and protecting high-value physical assets and sensitive materials. Their unique solutions provide unprecedented levels of real-time security and “sensing” of key assets, whether stationary or in transit, indoors or outdoors.